afinitor everolimus tablets 5mg 30tablets per box

Description

Indication & Scope

Everolimus Tablets (Afinitor®) is selective mTOR inhibitor. It blocks mTOR serine/threonine kinase pathway, inhibits tumor cell proliferation, angiogenesis and glucose metabolism, slows tumor progression for multiple solid tumors and TSC-related benign lesions.

Mechanism
Suppress mTOR signaling pathway, inhibit tumor proliferation and angiogenesis
Drug class
Oral mTOR-targeted film-coated tablets
Clinical use
Advanced kidney cancer, hormone-positive advanced breast cancer, progressive pancreatic neuroendocrine tumor, tuberous sclerosis complex associated tumors

Specification

Generic Name	Everolimus Tablets
Brand Name	Afinitor®
Ingredient	Everolimus
Dosage Form	Film-coated Tablets
Package	5mg*30 tablets/box
Conditions Treated	Combined with lenvatinib for advanced renal cell carcinoma after one prior anti-angiogenic systemic therapy; Unresectable, locally advanced or metastatic well-differentiated pancreatic neuroendocrine tumors (pNET) with progressive disease; Progressive, unresectable or metastatic hormone receptor positive, HER2 negative advanced breast cancer after failure of non-steroidal aromatase inhibitor
Taboos	Hypersensitivity to everolimus, sirolimus or excipients; pregnancy and lactation
Place of origin	Stein, Switzerland
Priscription Type	Prescription drug (Rx)
Storage Conditions	Seal and store below 25°C, avoid light and moisture
Manufacturer	Novartis Pharma Stein AG
Registration Authority	National Medical Products Administration (NMPA)
Approval number	HJ20171145
Approval Date	March 30, 2022
Shelf Life	36 months

How to use ?

Recommended Dose: Advanced RCC / advanced breast cancer / progressive pNET: 10mg once daily continuous oral administration; TSC-related SEGA / renal angiomyolipoma: Initial dose 4.5mg/m² once daily, adjust based on blood trough concentration

Time: Take at the same time every day, consistently with or without food, swallow whole without crushing/chewing

Interaction: Strong CYP3A4 inhibitors significantly increase everolimus exposure; strong CYP3A4 inducers reduce efficacy, avoid concomitant use

Side effects: Stomatitis, fatigue, diarrhea, rash, infections, hyperlipidemia; severe risks: interstitial lung disease, severe infection, oral ulceration, myelosuppression

Important Notice

This product shall only be used for post-exposure rabies prophylaxis by professional medical staff. It must be applied combined with rabies vaccine and injected via wound infiltration plus intramuscular routes as specified. Do not administer intravenously or alter the dosage at will. Hypersensitivity monitoring is required throughout the whole injection process.

Packaging & Shipping

Packaging

Original manufacturer’s packaging with secure export carton. Customized export packaging is available upon request.

Shipping Methods

Express Courier (EMS, DHL, FedEx, UPS), Air Freight, and Sea Freight. Cold-chain transportation is available for products requiring temperature-controlled logistics.

Export Support

Certificate of Analysis

GMP Certificate

Commercial Invoice

Packing List & CPP

Cold Chain Logistics

Customs Documentation

Scientific and regulatory sources

1.WHO References

2.NMPA

3.FDA

4.EMA

FAQ

Does everolimus cause hair loss?

Hair loss rarely happens with Afinitor monotherapy but may occur when combined with exemestane, which frequently causes alopecia; 15% of patients developed hair loss on exemestane alone in a clinical trial.

What pancreatic tumor can everolimus treat?

Progressive well-differentiated pancreatic neuroendocrine tumors.

What is the most typical adverse reaction of everolimus?

Stomatitis.

Can I expose myself to sunlight while taking everolimus?

Stay out of direct sunlight, especially between the hours of 10:00 AM and 3:00 PM, if possible.